1cP-LSD: Difference between revisions - PsychonautWiki Archive

Line 3:

'''1-Cyclopropionyl-''d''-lysergic acid diethylamide''' (also known as '''1cP-LSD''') is a lesser-known novel [[Psychoactive class::psychedelic]] substance of the [[Chemical class::lysergamide]] class. It is chemically similar to [[LSD]] and other LSD analogs like [[1B-LSD]], [[ALD-52]], and [[1P-LSD]]. Its mechanism of action is not well-studied, but is thought to produce its effects via stimulation of [[serotonin]] [[receptors]] in parts of the brain.<ref name="Brandt2020">{{cite journal|title=Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1‐cyclopropanoyl‐d‐lysergic acid diethylamide (1CP‐LSD)|first1=Simon D.|last1=Brandt|first2=Pierce V.|last2=Kavanagh|first3=Folker|last3=Westphal|first4=Alexander|last4=Stratford|first5=Anna U.|last5=Odland|first6=Adam K.|last6=Klein|first7=Geraldine|last7=Dowling|first8=Nicola M.|last8=Dempster|first9=Jason|last9=Wallach|first10=Torsten|last10=Passie|first11=Adam L.|last11=Halberstadt|date=March 16, 2020|doi=10.1002/dta.2789|volume=12|issue=6|journal=Drug Testing and Analysis|pages=812-826|eissn=1942-7611|issn=1942-7603|oclc=231680670|pmid=32180350}}</ref>

The origins of 1cP-LSD are not well-documented. Following 1P-LSD's prohibition in Germany, 1cP-LSD appeared on the online [[research chemical]] market in 2019.{{citation needed}} Like other LSD analogs, it was marketed as a legal alternative to LSD and 1P-LSD.

[[Subjective effects]] ~~are reportedly nearly-identical to [[LSD]] and~~ include [[geometry|open and closed eye visuals]], [[time distortion]], [[conceptual thinking]], [[introspection|enhanced introspection]], [[euphoria]], and [[ego loss]]. A study found that incubation of 1cP‐LSD with human serum led to the formation of LSD, indicating that it may act as a [[prodrug]] for LSD.<ref name="Brandt2020"></ref> Anecdotal reports ~~are~~ consistent with this theory.

[[Subjective effects]] include [[geometry|open and closed eye visuals]], [[time distortion]], [[conceptual thinking]], [[introspection|enhanced introspection]], [[euphoria]], and [[ego loss]]. A study found that incubation of 1cP‐LSD with human serum led to the formation of LSD, indicating that it may act as a [[prodrug]] for LSD.<ref name="Brandt2020"></ref> Anecdotal reports appear to be consistent with this theory, with most users reporting near-identical effects as LSD.

Limited data exist on the pharmacology, metabolism, and toxicity of 1cP-LSD. While it is presumed to have a [[LSD#Toxicity and harm potential|similar risk profile as LSD]] and its analogs, which are generally thought to be safe, more research is needed. It is highly advised to use [[harm reduction practices]] if using this substance.

Limited data exist on the pharmacology, metabolism, and toxicity of 1cP-LSD. While it is presumed to have a [[LSD#Toxicity and harm potential|similar risk profile as LSD]] and its analogs, which are generally thought to be safe in controlled settings, more research is needed. It is highly advised to use [[harm reduction practices]] if using this substance.

==History and culture==

1cP-LSD first appeared on the online research chemical market in July 2019.<ref>{{cite web|title=1cP-LSD|publisher=Google Trends|access-date=July 14, 2020|url=https://trends.google.com/trends/explore?date=all&q=1cp-lsd}}</ref>

1cP-LSD first appeared on the online research chemical market in July 2019.<ref>{{cite web|title=1cP-LSD|publisher=Google Trends|access-date=July 14, 2020|url=https://trends.google.com/trends/explore?date=all&q=1cp-lsd}}</ref> It was released shortly after the prohibition of 1P-LSD in Germany. It is part of a larger series of designer LSD analogs that have appeared on the research chemical market since the mid-2010s. These include [[AL-LAD]], [[ETH-LAD]], and [[ALD-52]].

==Chemistry==

Line 156:

It is strongly recommended that one uses [[responsible drug use|harm reduction practices]] when using this substance.

===Overdose===

1cP-LSD has no known toxic dose. However, higher doses increase the risk of adverse psychological reactions. These reactions include [[anxiety]], [[delusions]] and [[panic attacks]]. Medical attention is usually not needed except in the case of severe psychotic episodes or the ingestion of [[fake acid]] (such as [[25i-NBOMe]] or [[DOB]]). Administration of [[benzodiazepines]] or [[antipsychotics]] can help to relieve the acute negative cognitive effects of 1cP-LSD.

===~~Tolerance~~ and ~~addiction~~ potential===

===Dependence and abuse potential===

Although no formal studies have been conducted, it is assumed that like LSD itself, 1cP-LSD is [[Addiction potential::non-addictive with a low abuse potential]]. There are no literature reports of successful attempts to train animals to self-administer LSD — an animal model predictive of abuse liability — indicating that it does not have the necessary pharmacology to either initiate or maintain dependence.<ref>{{cite journal|last1=Nichols|first1=David E.|author-link=David E. Nichols|year=2004|title=Hallucinogens|journal=Pharmacology & Therapeutics|volume=101|issue=2|pages=131-181|doi=10.1016/j.pharmthera.2003.11.002|issn=0163-7258}}</ref> Likewise, there is virtually no withdrawal syndrome when chronic use of LSD is stopped.{{citation needed}} It is likely that 1cP-LSD does not deviate from LSD in this respect.

Tolerance to the effects of 1cP-LSD are built [[Time to full tolerance::almost immediately after ingestion]]. After that, it takes about [[Time to half tolerance::5-7 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::14 days]] to be back at baseline (in the absence of further consumption). 1cP-LSD produces cross-tolerance with [[Cross-tolerance::all [[psychedelic]]s]], meaning that after the use of 1cP-LSD they will have a reduced effect.

===Dangerous interactions===

~~{{DangerousInteractions}}~~

The following substances are listed on the assumption that 1cP-LSD possesses a similar if not the same dangerous interactions profile as [[LSD]], and may include more due to its status as an unstudied research chemical.

@@ Line 3: / Line 3: @@
 '''1-Cyclopropionyl-''d''-lysergic acid diethylamide''' (also known as '''1cP-LSD''') is a lesser-known novel [[Psychoactive class::psychedelic]] substance of the [[Chemical class::lysergamide]] class. It is chemically similar to [[LSD]] and other LSD analogs like [[1B-LSD]], [[ALD-52]], and [[1P-LSD]]. Its mechanism of action is not well-studied, but is thought to produce its effects via stimulation of [[serotonin]] [[receptors]] in parts of the brain.<ref name="Brandt2020">{{cite journal|title=Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1‐cyclopropanoyl‐d‐lysergic acid diethylamide (1CP‐LSD)|first1=Simon D.|last1=Brandt|first2=Pierce V.|last2=Kavanagh|first3=Folker|last3=Westphal|first4=Alexander|last4=Stratford|first5=Anna U.|last5=Odland|first6=Adam K.|last6=Klein|first7=Geraldine|last7=Dowling|first8=Nicola M.|last8=Dempster|first9=Jason|last9=Wallach|first10=Torsten|last10=Passie|first11=Adam L.|last11=Halberstadt|date=March 16, 2020|doi=10.1002/dta.2789|volume=12|issue=6|journal=Drug Testing and Analysis|pages=812-826|eissn=1942-7611|issn=1942-7603|oclc=231680670|pmid=32180350}}</ref>
 The origins of 1cP-LSD are not well-documented. Following 1P-LSD's prohibition in Germany, 1cP-LSD appeared on the online [[research chemical]] market in 2019.{{citation needed}} Like other LSD analogs, it was marketed as a legal alternative to LSD and 1P-LSD.
-[[Subjective effects]] are reportedly nearly-identical to [[LSD]] and include [[geometry|open and closed eye visuals]], [[time distortion]], [[conceptual thinking]], [[introspection|enhanced introspection]], [[euphoria]], and [[ego loss]]. A study found that incubation of 1cP‐LSD with human serum led to the formation of LSD, indicating that it may act as a [[prodrug]] for LSD.<ref name="Brandt2020"></ref> Anecdotal reports are consistent with this theory.
+[[Subjective effects]] include [[geometry|open and closed eye visuals]], [[time distortion]], [[conceptual thinking]], [[introspection|enhanced introspection]], [[euphoria]], and [[ego loss]]. A study found that incubation of 1cP‐LSD with human serum led to the formation of LSD, indicating that it may act as a [[prodrug]] for LSD.<ref name="Brandt2020"></ref> Anecdotal reports appear to be consistent with this theory, with most users reporting near-identical effects as LSD.
-Limited data exist on the pharmacology, metabolism, and toxicity of 1cP-LSD. While it is presumed to have a [[LSD#Toxicity and harm potential|similar risk profile as LSD]] and its analogs, which are generally thought to be safe, more research is needed. It is highly advised to use [[harm reduction practices]] if using this substance.
+Limited data exist on the pharmacology, metabolism, and toxicity of 1cP-LSD. While it is presumed to have a [[LSD#Toxicity and harm potential|similar risk profile as LSD]] and its analogs, which are generally thought to be safe in controlled settings, more research is needed. It is highly advised to use [[harm reduction practices]] if using this substance.
 ==History and culture==
 {{historyStub}}
-cP-LSD first appeared on the online research chemical market in July 2019.<ref>{{cite web|title=1cP-LSD|publisher=Google Trends|access-date=July 14, 2020|url=https://trends.google.com/trends/explore?date=all&q=1cp-lsd}}</ref>
+cP-LSD first appeared on the online research chemical market in July 2019.<ref>{{cite web|title=1cP-LSD|publisher=Google Trends|access-date=July 14, 2020|url=https://trends.google.com/trends/explore?date=all&q=1cp-lsd}}</ref> It was released shortly after the prohibition of 1P-LSD in Germany. It is part of a larger series of designer LSD analogs that have appeared on the research chemical market since the mid-2010s. These include [[AL-LAD]], [[ETH-LAD]], and [[ALD-52]].
 ==Chemistry==
@@ Line 156: / Line 156: @@
 It is strongly recommended that one uses [[responsible drug use|harm reduction practices]] when using this substance.
 ===Overdose===
 cP-LSD has no known toxic dose. However, higher doses increase the risk of adverse psychological reactions. These reactions include [[anxiety]], [[delusions]] and [[panic attacks]]. Medical attention is usually not needed except in the case of severe psychotic episodes or the ingestion of [[fake acid]] (such as [[25i-NBOMe]] or [[DOB]]). Administration of [[benzodiazepines]] or [[antipsychotics]] can help to relieve the acute negative cognitive effects of 1cP-LSD.
-===Tolerance and addiction potential===
+===Dependence and abuse potential===
+Although no formal studies have been conducted, it is assumed that like LSD itself, 1cP-LSD is [[Addiction potential::non-addictive with a low abuse potential]]. There are no literature reports of successful attempts to train animals to self-administer LSD — an animal model predictive of abuse liability — indicating that it does not have the necessary pharmacology to either initiate or maintain dependence.<ref>{{cite journal|last1=Nichols|first1=David E.|author-link=David E. Nichols|year=2004|title=Hallucinogens|journal=Pharmacology & Therapeutics|volume=101|issue=2|pages=131-181|doi=10.1016/j.pharmthera.2003.11.002|issn=0163-7258}}</ref> Likewise, there is virtually no withdrawal syndrome when chronic use of LSD is stopped.{{citation needed}} It is likely that 1cP-LSD does not deviate from LSD in this respect.
+Tolerance to the effects of 1cP-LSD are built [[Time to full tolerance::almost immediately after ingestion]]. After that, it takes about [[Time to half tolerance::5-7 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::14 days]] to be back at baseline (in the absence of further consumption). 1cP-LSD produces cross-tolerance with [[Cross-tolerance::all [[psychedelic]]s]], meaning that after the use of 1cP-LSD they will have a reduced effect.
 ===Dangerous interactions===
-{{DangerousInteractions}}
 {{DangerousInteractions/Intro}}
 The following substances are listed on the assumption that 1cP-LSD possesses a similar if not the same dangerous interactions profile as [[LSD]], and may include more due to its status as an unstudied research chemical.